A Functional Pipeline of Genome-Wide Association Data Leads to Midostaurin as a Repurposed Drug for Alzheimer’s Disease
Authors:
- Alvaro Esteban-MartosAEAlvaro Esteban-Martos
- Ana Maria Brokate-LlanosABAna Maria Brokate-Llanos
- Luis Miguel RealLRLuis Miguel Real
- Sonia Melgar-LocatelliSMSonia Melgar-Locatelli
- Itziar de RojasIRItziar de Rojas
- Adriana Castro-ZavalaACAdriana Castro-Zavala
- Maria Jose BravoMBMaria Jose Bravo
- Maria del Carmen Mañas-PadillaMMMaria del Carmen Mañas-Padilla
- Pablo García-GonzálezPGPablo García-González
- Maximiliano Ruiz-GaldonMRMaximiliano Ruiz-Galdon
- Beatriz Pacheco-SánchezBPBeatriz Pacheco-Sánchez
- Rocío PolvilloRPRocío Polvillo
Open Access
- 28 July 2023
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (15) , 12079
Abstract
Genome-wide association studies (GWAS) constitute a powerful tool to identify the different biochemical pathways associated with disease. This knowledge can be used to prioritize drugs targeting these routes, paving the road to clinical application. Here, we describe DAGGER (Drug Repositioning by Analysis of GWAS and Gene Expression in R), a straightforward pipeline to find currently approved drugs with repurposing potential. As a proof of concept, we analyzed a meta-GWAS of 1.6 × 107 single-nucleotide polymorphisms performed on Alzheimer’s disease (AD). Our pipeline uses the Genotype-Tissue Expression (GTEx) and Drug Gene Interaction (DGI) databases for a rational prioritization of 22 druggable targets. Next, we performed a two-stage in vivo functional assay. We used a C. elegans humanized model over-expressing the Aβ1-42 peptide. We assayed the five top-scoring candidate drugs, finding midostaurin, a multitarget protein kinase inhibitor, to be a protective drug. Next, 3xTg AD transgenic mice were used for a final evaluation of midostaurin’s effect. Behavioral testing after three weeks of 20 mg/kg intraperitoneal treatment revealed a significant improvement in behavior, including locomotion, anxiety-like behavior, and new-place recognition. Altogether, we consider that our pipeline might be a useful tool for drug repurposing in complex diseases.Keywords
Funding Information
- Programa Operativo FEDER (UMA20-FEDERJA-133, 83/23.04.2021, CNV-304-PRF-866, FI20/00215, PI13/02434, PI16/01861, PI17/01474, PI19/01240, PI19/01301, PID2020-120463RB-I00, POSTDOC21_00365, IFI21/00024, FPU17/00276, CP19/00068, PND2020/048)
- Fundacion SantÁngela (UMA20-FEDERJA-133, 83/23.04.2021, CNV-304-PRF-866, FI20/00215, PI13/02434, PI16/01861, PI17/01474, PI19/01240, PI19/01301, PID2020-120463RB-I00, POSTDOC21_00365, IFI21/00024, FPU17/00276, CP19/00068, PND2020/048)
- CIBERNED (UMA20-FEDERJA-133, 83/23.04.2021, CNV-304-PRF-866, FI20/00215, PI13/02434, PI16/01861, PI17/01474, PI19/01240, PI19/01301, PID2020-120463RB-I00, POSTDOC21_00365, IFI21/00024, FPU17/00276, CP19/00068, PND2020/048)
- Instituto de Salud Carlos III (UMA20-FEDERJA-133, 83/23.04.2021, CNV-304-PRF-866, FI20/00215, PI13/02434, PI16/01861, PI17/01474, PI19/01240, PI19/01301, PID2020-120463RB-I00, POSTDOC21_00365, IFI21/00024, FPU17/00276, CP19/00068, PND2020/048)
- National grants (UMA20-FEDERJA-133, 83/23.04.2021, CNV-304-PRF-866, FI20/00215, PI13/02434, PI16/01861, PI17/01474, PI19/01240, PI19/01301, PID2020-120463RB-I00, POSTDOC21_00365, IFI21/00024, FPU17/00276, CP19/00068, PND2020/048)
- Spanish Ministerio de Ciencia e Innovación (UMA20-FEDERJA-133, 83/23.04.2021, CNV-304-PRF-866, FI20/00215, PI13/02434, PI16/01861, PI17/01474, PI19/01240, PI19/01301, PID2020-120463RB-I00, POSTDOC21_00365, IFI21/00024, FPU17/00276, CP19/00068, PND2020/048)
- Secretaría General de Universidades, Investigación y Tecnología–Junta de Andalucía (UMA20-FEDERJA-133, 83/23.04.2021, CNV-304-PRF-866, FI20/00215, PI13/02434, PI16/01861, PI17/01474, PI19/01240, PI19/01301, PID2020-120463RB-I00, POSTDOC21_00365, IFI21/00024, FPU17/00276, CP19/00068, PND2020/048)
- National System of Health (UMA20-FEDERJA-133, 83/23.04.2021, CNV-304-PRF-866, FI20/00215, PI13/02434, PI16/01861, PI17/01474, PI19/01240, PI19/01301, PID2020-120463RB-I00, POSTDOC21_00365, IFI21/00024, FPU17/00276, CP19/00068, PND2020/048)
- Spanish Ministry of Science, Innovation and Universities (UMA20-FEDERJA-133, 83/23.04.2021, CNV-304-PRF-866, FI20/00215, PI13/02434, PI16/01861, PI17/01474, PI19/01240, PI19/01301, PID2020-120463RB-I00, POSTDOC21_00365, IFI21/00024, FPU17/00276, CP19/00068, PND2020/048)
- European Social Fund (UMA20-FEDERJA-133, 83/23.04.2021, CNV-304-PRF-866, FI20/00215, PI13/02434, PI16/01861, PI17/01474, PI19/01240, PI19/01301, PID2020-120463RB-I00, POSTDOC21_00365, IFI21/00024, FPU17/00276, CP19/00068, PND2020/048)
- Delegación del Gobierno para el Plan Nacional sobre Drogas, Ministerio de Salud, Gobierno de España (UMA20-FEDERJA-133, 83/23.04.2021, CNV-304-PRF-866, FI20/00215, PI13/02434, PI16/01861, PI17/01474, PI19/01240, PI19/01301, PID2020-120463RB-I00, POSTDOC21_00365, IFI21/00024, FPU17/00276, CP19/00068, PND2020/048)
- Universidad de Málaga (UMA20-FEDERJA-133, 83/23.04.2021, CNV-304-PRF-866, FI20/00215, PI13/02434, PI16/01861, PI17/01474, PI19/01240, PI19/01301, PID2020-120463RB-I00, POSTDOC21_00365, IFI21/00024, FPU17/00276, CP19/00068, PND2020/048)
This publication has 44 references indexed in Scilit:
- Genome scan in familial late-onset Alzheimer's disease: A locus on chromosome 6 contributes to age-at-onsetAmerican Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2013
- The Genetics of Alzheimer DiseaseCold Spring Harbor Perspectives in Medicine, 2012
- Utility of an improved model of amyloid-beta (Aβ1-42) toxicity in Caenorhabditis elegans for drug screening for Alzheimer’s diseaseMolecular Neurodegeneration, 2012
- Review Article: Genetics of Alzheimer DiseaseJournal of Geriatric Psychiatry and Neurology, 2010
- Probing the Binding Sites and Mechanisms of Action of Two Human Ether-a-go-go-Related Gene Channel Activators, 1,3-bis-(2-Hydroxy-5-trifluoromethyl-phenyl)-urea (NS1643) and 2-[2-(3,4-Dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-nicotinic acid (PD307243)Molecular Pharmacology, 2008
- How common are the “common” neurologic disorders?Neurology, 2007
- Ethological and temporal analyses of anxiety-like behavior: The elevated plus-maze model 20 years onNeuroscience & Biobehavioral Reviews, 2005
- Drug repositioning: identifying and developing new uses for existing drugsNature Reviews Drug Discovery, 2004
- Triple-Transgenic Model of Alzheimer's Disease with Plaques and TanglesNeuron, 2003
- Basic local alignment search toolJournal of Molecular Biology, 1990